Merck & Co., Inc. $MRK Shares Purchased by Merit Financial Group LLC

Key Points

• Merit Financial Group increased its Merck stake by 6.3% in the second quarter, adding 12,447 shares to hold 209,288 shares valued at approximately $26.9 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Merck reported quarterly revenue of $16.61 billion, ahead of expectations, while analysts maintain a “Moderate Buy” consensus with an average price target of $135.50. The stock recently traded near its 52-week high at $135.68.
• Investors continue to weigh Merck’s pipeline, Keytruda demand and $0.85 quarterly dividend against Keytruda patent-loss risk and substantial insider selling; insiders sold roughly $30 million of shares over the last quarter.

Merit Financial Group LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 6.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 209,288 shares of the company's stock after purchasing an additional 12,447 shares during the period. Merit Financial Group LLC's holdings in Merck & Co., Inc. were worth $26,893,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Kavar Capital Partners Group LLC lifted its position in shares of Merck & Co., Inc. by 1.0% in the 2nd quarter. Kavar Capital Partners Group LLC now owns 16,019 shares of the company's stock worth $2,058,000 after buying an additional 155 shares during the last quarter. Financial Advisory Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Financial Advisory Partners LLC now owns 17,793 shares of the company's stock valued at $2,286,000 after buying an additional 128 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its position in shares of Merck & Co., Inc. by 2.2% during the 2nd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 6,782 shares of the company's stock valued at $871,000 after buying an additional 145 shares during the last quarter. Palisade Asset Management LLC grew its position in shares of Merck & Co., Inc. by 0.6% during the 2nd quarter. Palisade Asset Management LLC now owns 35,395 shares of the company's stock valued at $4,548,000 after buying an additional 196 shares during the last quarter. Finally, Global Financial Private Client LLC raised its stake in Merck & Co., Inc. by 6.7% during the second quarter. Global Financial Private Client LLC now owns 39,125 shares of the company's stock worth $5,028,000 after acquiring an additional 2,470 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRK. Barclays raised their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Royal Bank Of Canada reiterated an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price target on the stock. Argus boosted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Morgan Stanley boosted their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a research report on Thursday, July 9th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $135.50.

Merck & Co., Inc. Stock Performance

MRK stock opened at $135.57 on Friday. The company has a 50-day simple moving average of $125.25 and a 200 day simple moving average of $119.83. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $334.49 billion, a P/E ratio of 108.46, a PEG ratio of 5.73 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.68.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same period in the previous year, the business earned $2.13 earnings per share. Merck & Co., Inc.'s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.5%. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the company's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Chirfi Guindo sold 10,000 shares of the company's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. This represents a 21.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company's stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source